CPHA Canvax

"The primary objectives of this statement are to review the evidence on the efficacy, effectiveness, immunogenicity and safety of the MenB-fHBP vaccine for the prevention of IMD caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. A literature review was also undertaken to identify cost-effectiveness studies of serogroup B protein-based meningococcal vaccines in developed countries. This evidence was used to develop recommendations for the use of the MenB-fHBP vaccine in Canada. The scope of this statement does not include comparative recommendations on the use of the MenB-fHBP vaccine (Trumenba® ) and the 4CMenB vaccine (Bexsero® )" - The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease 


Related Resources


Implementation Tool



Vaccine Safety and Development,Research and Development,Vaccine Effectiveness and Efficacy,Vaccine Preventable Diseases,Communicable Diseases,Meningococcal Disease Vaccine Safety and Development
Research and Development
Vaccine Effectiveness and Efficacy
Vaccine Preventable Diseases
Communicable Diseases
Meningococcal Disease


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.